In a recent study in the Journal of Translational Medicine, researchers from Azrieli Research Center (Canada) and collaborating institutions hypothesized that the dysregulation of SMPDL3B may be involved in myalgic encephalomyelitis (ME) progression, and investigated its role and clinical relevance in ME pathophysiology.